XCancer

Phase IIT Trial of SNA009

Description:

This clinical trial is a single-center, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics and radiation dosimetry of 68Ga-NODAGA-SNA009 in patients with colorectal cancer.

Sponsor:

SmartNuclide Biopharma

Phase:

Early Phase 1

Government Study Link:

NCT07597759 - Click here to see study on

ClinicalTrials.gov

SNA009

Isotope(s):
Target(s):
  • GPA33
Ligand Class: Antibodies
Chelator: NODAGA
Inclusion
  • Results of colonoscopy, CT, MRI or PET-CT scans performed within the past month (if available);
  • Patients with a confirmed diagnosis of colorectal cancer;
  • Pathology test results from within the past year
Exclusion
  • Patients with uncontrolled severe infections, or those with other serious comorbidities;
  • Patients deemed unsuitable for participation in this study by the investigator.
  • Patients with other clearly diagnosed malignant tumours;